Claudia Irene Cardenas, MD
Pediatrics · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Cardenas’s office at (650) 498-7103 to ask if they take your plan before you enroll.
California Medical Board record
Licence A96643 · Current
Licensed to practise in California · since 2006 · expires 2028-08-31 · Texas Tech University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$182,658 in 2024
Medicaid paid $182,658 for 3,277 billed services this clinician did in 2024, up to 102 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use | 136 | $38,891 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 336 | $37,348 |
| Short return visit (20+ min) | 255 | $23,962 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 194 | $19,049 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 713 | $16,741 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) | 341 | $11,191 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 77 | $8,551 |
| Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 240 | $5,342 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose | 77 | $3,707 |
| Screening test, pure tone, air only | 225 | $3,383 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 132 | $2,928 |
| Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use | 116 | $2,710 |
| 2024 | 3,277 | 20 | 102 | $182,658 |
| 2023 | 4,346 | 23 | 110 | $269,055 |
| 2022 | 3,307 | 19 | 85 | $232,528 |
| 2021 | 2,266 | 24 | 78 | $109,357 |
| 2020 | 2,942 | 25 | 66 | $101,554 |
| 2019 | 3,320 | 25 | 69 | $128,257 |
| 2018 | 4,190 | 27 | 137 | $232,938 |
See the largest Medicaid services in earlier years
2023
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 302 | $72,495 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 352 | $39,571 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 366 | $38,676 |
| Short return visit (20+ min) | 241 | $23,942 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 795 | $17,764 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) | 505 | $16,366 |
| Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use | 215 | $11,892 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 345 | $7,295 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 61 | $7,268 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 49 | $6,350 |
| Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use | 297 | $6,164 |
| Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use | 91 | $5,376 |
2022
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 289 | $69,843 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 419 | $45,211 |
| Short return visit (20+ min) | 210 | $20,965 |
| Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use | 250 | $17,422 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 109 | $12,986 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) | 404 | $12,962 |
| Initial hospital or birthing center care, per day, for evaluation and management of normal newborn infant | 184 | $11,952 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 532 | $10,373 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 145 | $8,109 |
| Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use | 111 | $7,696 |
| Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use | 273 | $6,948 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 151 | $3,157 |
2021
| Short return visit (20+ min) | 373 | $24,119 |
| Return visit (30+ min) | 237 | $19,840 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 171 | $16,698 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 102 | $12,354 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 104 | $9,116 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 54 | $3,500 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 161 | $3,171 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) | 98 | $2,959 |
| Initial hospital or birthing center care, per day, for evaluation and management of normal newborn infant | 36 | $2,868 |
| Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use | 43 | $2,843 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 142 | $2,809 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 26 | $1,820 |
2020
| Short return visit (20+ min) | 428 | $26,747 |
| Return visit (30+ min) | 268 | $25,871 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 145 | $10,080 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 138 | $9,590 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 91 | $6,370 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 79 | $5,530 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Influenza | 138 | $3,014 |
| Measurement of lead | 157 | $2,325 |
| Bilateral quantitative screening test of visual acuity | 373 | $1,805 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 91 | $1,781 |
| Screening test, pure tone, air only | 295 | $1,440 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 60 | $1,187 |
2019
| Return visit (30+ min) | 386 | $36,790 |
| Short return visit (20+ min) | 502 | $31,600 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 160 | $11,200 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 154 | $10,780 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 147 | $10,010 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 108 | $7,350 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Influenza | 130 | $2,740 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group A | 166 | $2,240 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 111 | $2,197 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 103 | $2,038 |
| Bilateral quantitative screening test of visual acuity | 332 | $1,625 |
| Screening test, pure tone, air only | 314 | $1,535 |
2018
| Return visit (30+ min) | 861 | $126,966 |
| Short return visit (20+ min) | 294 | $30,845 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 224 | $15,680 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 208 | $14,420 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 155 | $10,780 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 87 | $6,090 |
| Developmental screening | 200 | $3,600 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 141 | $2,751 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 200 | $2,512 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Influenza | 115 | $2,448 |
| Measurement of lead | 155 | $2,310 |
| Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure breathing (IPPB) device | 59 | $2,021 |
Money from drug and device companies
$20 in 2020
| 2020 | 1 | 1 | None | $20 |
| 2019 | 3 | 5 | None | $82 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sanofi Pasteur | Adacel | $20 | 1 payment
|
See the published payment
| Sanofi Pasteur | Meals · 2020-03-03 | Adacel | $20 |
See earlier years (2019)
2019: $82
| Ironshore Pharmaceuticals | Jornay Pm 20mg Capsules (Bottle of 100) | $33 | 2 payments
|
| Sobi | Synagis | $25 | 1 payment
|
| Pfizer | Prevnar - 13 | $24 | 2 payments
|
Professional record
- NPI
- 1407045750
- Licence
- CA A96643California A96643: Current · expires 2028-08-31
More record details
- Sole proprietor
- No
- Taxonomy
- Pediatrics (208000000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-10-22
- NPI last updated
- 2021-12-07
- NPI record certified
- 2021-12-07
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.